Zhifei’s Second-generation Recombinant COVID-19 Vaccine Starts International Clinical Trial

 Source: Xinhua News Agency

The launch ceremony of the international clinical trial of the Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell) was recently held simultaneously in Uzbekistan and China. Uzbekistan became the first overseas clinical trial site for Zhifei’s second-generation recombinant COVID-19 vaccine, marking another important collaboration between China and Uzbekistan in the field of anti-epidemic and biomedicine.

According to the press release, the second-generation recombinant COVID-19 vaccine’s antigen is designed for Omicron and Delta variants, and is jointly developed by the Institute of Microbiology, Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. Compared with the original Recombinant COVID-19 Vaccine (CHO Cell), the second-generation vaccine covers the nowadays widely-spread Omicron subvariants and is able to induce a broader and stronger immune response.

Uzbekistan is the first country to conduct the international multi-region phase III clinical trial of the original Recombinant COVID-19 Vaccine (CHO Cell), which was approved for conditional marketing in China in March this year and has already provided protection for over 100 million people worldwide. At a time when Omicron variants are still circulating across the globe, China and Uzbekistan are actively engaged in the anti-epidemic collaboration, which will contribute more wisdom and strength to the fight against COVID-19.